Oruka Therapeutics, Inc. (ORKA)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (34.1M) | (34.4M) | (36.4M) | (50.1M) |
| Net Income | (30.3M) | (29.6M) | (31.8M) | (41.2M) |
| Diluted EPS | $-0.55 | N/A | $-0.48 | $-0.55 |
Annual Financials
| Metric | 2025-12-31 |
|---|---|
| Revenue | 0.00 |
| Operating Income | (122.1M) |
| Net Income | (105.4M) |
| Diluted EPS | $-1.85 |